Health Condition 1: N189- Chronic kidney disease, unspecified
Conditions
Interventions
Intervention1: ezetimibe plus atorvastatin: Ezetimibe- cholestrol lowering agent that inhibits absorption o cholestrol from gastroinestinal and biliary systems.
Dose of Ezetimibe -10 mg/day, orally
Du
HMG CoA inhibitor.
Dose of Atorvastatin- 40 mg/day, orally
Duration -4 weeks
Control Intervention1: Atorvastatin: Atorvastatin- lipid lowering agent
HMG CoA inhibitor.
Dose-40 mg/ day, orally
Duration- 4weeks.
Sponsors
Dr Dolly Narwal
Eligibility
Inclusion criteria
Inclusion criteria: 1. Who gives consent. 2. Patients with Chronic Kidney Disease between Age group of 40-60 years. 3. On Conservative Management for Chronic Kidney Disease. 4. As evidenced radiologically (Bilateral Shruken Kidney /Loss of corticomedullary differentiation) or biochemically (elevated blood urea, serum creatinine) for more than 3 months. 5. With known Chronic Kidney Disease irrespective of the etiology.
Exclusion criteria
Exclusion criteria: 1. Patients with Acute renal failure and Nephrotic syndrome. 2. Patients on drugs affecting Lipid metabolism like Beta Blockers, steroids and Oral contraceptive pills. 3. Female patients who are pregnant. 4. Known Hypothyroidism patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| effect of drug atorvastatin and atorvastatin plus ezetimibe on lipid profile in chronic kidney disease patients.Timepoint: 4 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To monitor the differences between the two regimens with respect to effect size profile within follow up period.Timepoint: 4 weeks | — |
Countries
India
Contacts
Public ContactDr Dolly Narwal
MAMC AGROHA
Outcome results
None listed